LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

Kodu・Aktsiate loetelu・IQVIA Holdings Inc

IQVIA Holdings Inc

Suletud

SektorTervishoid

174.6 0.69

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

170.51

Max

176.13

Põhinäitajad
By Trading Economics
Sissetulek	-239M 275M
Müük	-213M 4.2B
P/E Sektori keskmine	21.559 49.8
Aktsiakasum	2.9
Kasumimarginaal	6.625
Töötajad	93,000
EBITDA	-245M 802M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+22.54% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	21. juuli 2026

Turustatistika
By TradingEconomics
Turukapital	1.9B 29B
Eelmine avamishind	173.91
Eelmine sulgemishind	174.6

Uudiste sentiment

By Acuity

30%

70%

83 / 346 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bullish Evidence

150.68 / 153.45 Toetus ja vastupanu

IQVIA Holdings Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

12. mai 2026, 22:50 UTC

Tulu

Commonwealth Bank of Australia Increases Provisions as 3Q Profit Slips

12. mai 2026, 22:49 UTC

Tulu

Aristocrat Leisure Raises Midyear Dividend, Swells Share Buyback Program

12. mai 2026, 22:32 UTC

Tulu

JBS 1Q Profit Slides Amid Rising Cattle Costs -- Update

12. mai 2026, 23:48 UTC

Market Talk

Nikkei May Decline Amid Uncertainty Over Iran Conflict -- Market Talk

12. mai 2026, 22:57 UTC

Market Talk

Tulu

JBS Says Consumers Are Looking to Pork for Affordable Protein -- Market Talk

12. mai 2026, 22:26 UTC

Tulu

Aristocrat Leisure to Increase On-Market Share Buyback by A$1 Billion

12. mai 2026, 22:25 UTC

Tulu

Aristocrat Leisure 1H Normalized Pretax Profit A$997.3 Million, Up 9.4% on Year

12. mai 2026, 22:25 UTC

Tulu

Aristocrat Leisure Interim Dividend A$0.50/Security

12. mai 2026, 22:24 UTC

Tulu

Aristocrat Leisure 1H Revenue From Continuing Operations A$3.03 Billion, Down 0.2% on Year

12. mai 2026, 22:23 UTC

Tulu

Aristocrat Leisure 1H Net Profit From Discontinued Operations A$7.0 Million

12. mai 2026, 22:23 UTC

Tulu

Aristocrat Leisure 1H Net Profit From Continuing Operations A$798.5 Million, Up 56%

12. mai 2026, 22:19 UTC

Tulu

CBA: Total Provision Coverage Ratio 1.57%>CBA.AU

12. mai 2026, 22:14 UTC

Tulu

CBA: Business Lending Continued to Grow Above System>CBA.AU

12. mai 2026, 22:14 UTC

Tulu

CBA Had 1.4M Business Transaction Accounts at March 31, Up 7% on Year>CBA.AU

12. mai 2026, 22:13 UTC

Tulu

CBA Household Deposits Grew A$38B in 12 Months Through March>CBA.AU

12. mai 2026, 22:12 UTC

Tulu

CBA Home Loan Balances Grew A$41B in 12 Months Through March>CBA.AU

12. mai 2026, 22:12 UTC

Tulu

CBA 3Q New Home Loan Funding A$45B>CBA.AU

12. mai 2026, 22:11 UTC

Tulu

Correct: JBS NV 1Q EPS 20c, Not 21c >JBS

12. mai 2026, 22:11 UTC

Tulu

CBA: CET1 Level 2 Capital Ratio 11.6%>CBA.AU

12. mai 2026, 22:10 UTC

Tulu

CBA: Customer Deposit Funding Ratio 79%>CBA.AU

12. mai 2026, 22:09 UTC

Tulu

CBA: Underlying Portfolio Credit Quality Remains Sound>CBA.AU

12. mai 2026, 22:09 UTC

Tulu

CBA: Higher Collective Provisions Reflect Geopolitical, Macroeconomic Uncertainty >CBA.AU

12. mai 2026, 22:08 UTC

Tulu

CBA 3Q Loan Impairment Expense A$316M>CBA.AU

12. mai 2026, 22:07 UTC

Tulu

CBA: Costs Up on Higher Cloud Computing Volumes, Software Licenses, AI Investment>CBA.AU

12. mai 2026, 22:06 UTC

Tulu

CBA 3Q Operating Expenses Up 1% Excluding Restructuring, Notable Items>CBA.AU

12. mai 2026, 22:06 UTC

Tulu

CBA: 3Q Underlying Net Interest Margin Was Broadly Stable>CBA.AU

12. mai 2026, 22:05 UTC

Tulu

CBA: Lending, Deposit Volume Growth Offset Impact of Two Fewer Days >CBA.AU

12. mai 2026, 22:04 UTC

Tulu

Commonwealth Bank: Operating Income Flat in March Quarter >CBA.AU

12. mai 2026, 22:04 UTC

Tulu

Commonwealth Bank 3Q Cash Profit Up 4% on Year>CBA.AU

12. mai 2026, 22:04 UTC

Tulu

Commonwealth Bank 3Q Cash Profit Down 1% on 1H Quarterly Average>CBA.AU

Võrdlus sarnastega

Hinnamuutus

IQVIA Holdings Inc Prognoos

Hinnasiht

By TipRanks

22.54% tõus

12 kuu keskmine prognoos

Keskmine 212.67 USD 22.54%

Kõrge 240 USD

Madal 185 USD

Põhineb 11 Wall Streeti analüütiku instrumendi IQVIA Holdings Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

11 ratings

Osta

Hoia

Müü

Põhineb 11 analüütiku instrumendi IQVIA Holdings Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

150.68 / 153.45Toetus ja vastupanu

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

All events are bearish.

Sentiment

By Acuity

83 / 346 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest IQVIA Holdings Inc

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE; and a strategic collaboration with NVIDIA Corporation. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.